First two medicinal products to undergo EU joint clinical assessments announced
The EU-wide JCAs come with both advantages and disadvantages.
Pricing and Market Access
IRA holds the scope to shape pharma’s research strategy, say experts
International Reference Pricing (IRP) 2024: A year in review
Vietnam eases foreign investment restrictions in amended pharmaceutical law
Key pharma launch trends in 2024
All change in Germany – confidential pricing in, IRP out
MHRA launches refreshed ILAP to speed up NHS drug access
Novo Nordisk’s Ozempic named in latest Medicare price negotiations
